Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. (Record no. 16113087)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02205 a2200625 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250515015538.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 200604s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 0008-543X |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1002/cncr.21776 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Thomas, Deborah A |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20060425 |
| 245 00 - TITLE STATEMENT | |
| Title | Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Cancer |
| Date of publication, distribution, etc. | Apr 2006 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1569-80 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Clinical Trial; Journal Article |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antibodies, Monoclonal |
| General subdivision | therapeutic use |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antibodies, Monoclonal, Murine-Derived |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic Agents |
| General subdivision | therapeutic use |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic Combined Chemotherapy Protocols |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Burkitt Lymphoma |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Combined Modality Therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Cyclophosphamide |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Dexamethasone |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Doxorubicin |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug Administration Schedule |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Female |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Immunotherapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Infusions, Intravenous |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Male |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Middle Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Precursor Cell Lymphoblastic Leukemia-Lymphoma |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Rituximab |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Survival Analysis |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Treatment Outcome |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Vincristine |
| General subdivision | administration & dosage |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Faderl, Stefan |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | O'Brien, Susan |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Bueso-Ramos, Carlos |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Cortes, Jorge |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Garcia-Manero, Guillermo |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Giles, Francis J |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Verstovsek, Srdan |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Wierda, William G |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Pierce, Sherry A |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Shan, Jianqin |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Brandt, Mark |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hagemeister, Fredrick B |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Keating, Michael J |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Cabanillas, Fernando |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kantarjian, Hagop |
| 773 0# - HOST ITEM ENTRY | |
| Title | Cancer |
| Related parts | vol. 106 |
| -- | no. 7 |
| -- | p. 1569-80 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1002/cncr.21776">https://doi.org/10.1002/cncr.21776</a> |
| Public note | Available from publisher's website |
No items available.